2022
Radiation-associated angiosarcoma of the breast: An international multicenter analysis
MERGANCOVA, Jana, Anna LIEROVA, Oldřich COUFAL, Jan ZATECKY, Bohuslav MELICHAR et. al.Základní údaje
Originální název
Radiation-associated angiosarcoma of the breast: An international multicenter analysis
Autoři
MERGANCOVA, Jana (203 Česká republika), Anna LIEROVA (203 Česká republika), Oldřich COUFAL (203 Česká republika, domácí), Jan ZATECKY (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Ilona ZEDNIKOVA (203 Česká republika), Jindriska MERGANCOVA (203 Česká republika), Anna JESENKOVA (203 Česká republika), Karel STASTNY (203 Česká republika), Jiri GATEK (203 Česká republika), Otakar KUBALA (203 Česká republika), Jiri PROKOP (203 Česká republika), Daniel DYTTERT, Marian KARABA, Ivana SCHWARZBACHEROVA (203 Česká republika), Anna HUMENANSKA (203 Česká republika), Jindrich SUK (203 Česká republika), Michal VALENTA (203 Česká republika), Vladimir MOUCHA (203 Česká republika), Lukas SAKRA (203 Česká republika), Ales HLAVKA (203 Česká republika), Maria HACOVA (203 Česká republika), Radovan VOJTISEK (203 Česká republika), Marek SOCHOR (203 Česká republika), Tomas JIRASEK (203 Česká republika), Michaela ZABOJNIKOVA (203 Česká republika), Martina ZEMANOVA, Katarina MACHALEKOVA, Dominika RUSNAKOVA, Eva KUDELOVA a Marek SMOLAR (garant)
Vydání
SURGICAL ONCOLOGY-OXFORD, OXFORD, ELSEVIER SCI LTD, 2022, 0960-7404
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.300
Kód RIV
RIV/00216224:14110/22:00128320
Organizační jednotka
Lékařská fakulta
UT WoS
000789993900010
Klíčová slova anglicky
Radiation; Angiosarcoma; Breast; Multicenter study
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 27. 1. 2023 11:20, Mgr. Tereza Miškechová
Anotace
V originále
Introduction: Radiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports.Materials and methods: All patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated.Results: Data of 53 patients were analyzed. The median age at diagnosis was 72 (range 44-89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36-172) months. The median radiation dose was 57.6 (range 34-66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3-66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period.Conclusion: The present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear.